Beijing Hotgen Biotech Co Ltd
SSE:688068
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
CN |
Beijing Hotgen Biotech Co Ltd
SSE:688068
|
2.8B CNY | -33.9 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
228.4B USD | 27.2 | ||
US |
Danaher Corp
NYSE:DHR
|
186.3B USD | 26.8 | ||
US |
Agilent Technologies Inc
NYSE:A
|
43.3B USD | 22.1 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
41.6B USD | 19.3 | ||
CH |
Lonza Group AG
SIX:LONN
|
36.4B CHF | 26.1 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.6T KRW | 33.4 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
31.2B USD | 31.1 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
26.1B USD | 34.6 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
25.6B USD | 19.5 | ||
US |
Waters Corp
NYSE:WAT
|
20.7B USD | 31 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.